Genome engineering of stem cell organoids for disease modeling by unknown
REVIEW
Genome engineering of stem cell organoids
for disease modeling
Yingmin Sun1,2, Qiurong Ding1,2&
1 CAS Key Laboratory of Nutrition and Metabolism, Institute for Nutritional Sciences, Shanghai Institutes for Biological
Sciences, Chinese Academy of Sciences, Shanghai 200031, China
2 University of Chinese Academy of Sciences, Shanghai 200031, China
& Correspondence: qrding@sibs.ac.cn (Q. Ding)
Received November 30, 2016 Accepted December 28, 2016
ABSTRACT
Precision medicine emerges as a new approach that
takes into account individual variability. Successful
realization of precision medicine requires disease
models that are able to incorporate personalized dis-
ease information and recapitulate disease development
processes at the molecular, cellular and organ levels.
With recent development in stem cell ﬁeld, a variety of
tissue organoids can be derived from patient speciﬁc
pluripotent stem cells and adult stem cells. In combi-
nation with the state-of-the-art genome editing tools,
organoids can be further engineered to mimic disease-
relevant genetic and epigenetic status of a patient. This
has therefore enabled a rapid expansion of sophisti-
cated in vitro disease models, offering a unique system
for fundamental and biomedical research as well as the
development of personalized medicine. Here we sum-
marize some of the latest advances and future per-
spectives in engineering stem cell organoids for human
disease modeling.
KEYWORDS pluripotent/adult stem cell, tissue organoid,
genome editing, precision medicine
INTRODUCTION
The concept of precision medicine has been “hot” again in
the public spotlight in recent years. The fundamental idea
behind precision medicine is to integrate information from all
aspects to create diagnostic and therapeutic strategies that
are precisely tailored to each patient’s requirement (Collins
and Varmus, 2015). Recent advances in biotechnologies
have led to an explosion of disease relevant molecular
information, providing enormous opportunities to obtain the
pathophysiological insights to develop personalized treat-
ment. However, challenges exist that a model system is
urgently needed for interpreting the information. An ideal
system would have the following several features: 1) could
recapitulate human body functions and disease develop-
ment processes at different levels of molecular, cellular, tis-
sue or organ; 2) could incorporate personalized disease
information (e.g. genetic background, nutritional status,
environmental disturbance, etc.); and 3) could be cultured in
large scales for disease study and high-throughput drug
screenings.
The discovery that mature cells can be reprogrammed to
become pluripotent by Drs. John Gurdon and Shinya
Yamanaka has opened the door that pluripotent stem cells
from patients can be generated for disease modeling
(Takahashi et al., 2007; Yu et al., 2007). Human pluripotent
stem cells (hPSCs) as well as adult stem cells (ASCs)
derived from tissues offer a unique in vitro cellular model
system with several advantages. First, they have a human
genome and thus are the most appropriate for studying
human disease-relevant genetic variations. Second, under
appropriate culture conditions, the cells can be directed to
differentiate into a variety of terminal cell types. And the
in vitro differentiation process often recapitulates aspects of
normal development, providing the opportunity to study
developmental and degenerative processes. Third, they can
be maintained in culture for a large number of passages
while keeping the genome integrity, thus are able to generate
cellular materials in a large-scale for compound screenings.
In recent years, stem cells have been revealed to pos-
sess intrinsic abilities to generate complex structures in vitro
through self-organization (Eiraku et al., 2008; Gaspard et al.,
2008; Sato et al., 2009). When cultured in a 3D space and in
the presence of suitable exogenous factors, stem cells form











structures that mimic the architecture of a certain organ
in vitro—these 3D complex structures are thus termed
“organoids”. Compared to 2D monocultures of a single cell
type, organoids have the potential to recapitulate spatial
organization of heterogeneous tissue-speciﬁc cells, cell-cell
and cell-matrix interactions. Moreover, the emergence of
genome editing technologies over the past a few years has
made it feasible to efﬁciently engineer disease relevant
genetic variations into stem cells (Hsu et al., 2014; Wang
and Qi, 2016). Therefore, different organoids can be gen-
erated carrying patient speciﬁc disease-causing genetic and
epigenetic background. Altogether, this is offering a unique
model system for studying disease-relevant information and
development of precision medicine. In this review, we dis-
cuss how human stem cells are self-organized to form dif-
ferent kinds of organoids, and how these tissue organoids, in
combination with genome editing tools, can leverage our
understanding of human disease development and will
facilitate the realization of precision medicine. We will also
highlight some of the existing limitations or challenges as
well as future directions.
ORGANOID FORMATION
In general, organoids can be generated either from ASCs
derived from tissues, or from PSCs, including patient-derived
induced pluripotent stem cells (iPSCs). Stem cells are often
placed within a hydrogel (e.g. Matrigel) in a 3D culture sys-
tem, with supplement of suitable exogenous factors to mimic
biochemical and physical cues of tissue development. Cells
then exhibit some intrinsic ability to assemble into complex
structures termed as organoids. These organoids are con-
stituted of more than one cell type, often resemble archi-
tecture of a certain organ and exhibit some function speciﬁc
to that organ, and this in vitro formation process is termed as
“self-organization”.
Organoids derived from ASCs
The development of the intestinal organoid culture system in
2009wasamajor technological advance in thisﬁeld (Satoetal.,
2009). In this study, single Lgr5+ stem cells were isolated from
mouse intestinal epithelium and cultured in a simple 3D culture
system in which Matrigel was used as extra cellular matrix. A
few key growth factors, such as WNT, Noggin, R-spondin and
EGF, were supplemented mostly to maintain stem cell popu-
lations. Remarkably, these stem cells were found later to be
able to form continuously expanding crypt-villus organoids that
present near-physiological epithelium architecture reminiscent
of normal gut. A similar culture system was subsequently
adapted for generation of human intestinal organoids (Dekkers
et al., 2013). Moreover, Lgr5+ stem cells derived from other
organs were also found later to be able to self-organize to form
different organoids, including stomach, colon and liver (Barker
etal., 2010;Huchetal., 2013a,b;Satoet al., 2011;Stangeetal.,
2013). In summary, organoids that have been successfully
generated with ASCs from primary murine or human tissues
include intestine (mouse/human) (Dekkers et al., 2013; Sato
et al., 2009; Yin et al., 2014), stomach (mouse/human) (Barker
et al., 2010; Bartfeld et al., 2015; Schlaermann et al., 2016;
Stange et al., 2013), oesophagus (mouse/human) (DeWard
et al., 2014; Sato et al., 2011), colon (mouse/human) (Jung
et al., 2011; Sato et al., 2011), liver (mouse) (Huch et al., 2013b;
Huch et al., 2015), pancreas (mouse/human) (Boj et al., 2015;
Huch et al., 2013a), lingual (mouse) (Hisha et al., 2013), lung
(mouse) (Lee et al., 2014; Mondrinos et al., 2006; Mondrinos
et al., 2014), taste bud (mouse) (Aihara et al., 2015; Ren et al.,
2014), salivary gland (mouse) (Nanduri et al., 2014) and pros-
tate (mouse/human) (Chua et al., 2014; Gao et al., 2014; Kar-
thaus et al., 2014) (Table 1).
Organoids derived from PSCs
The use of PSCs to generate organoids circumvents the
limitation of availability of human primary tissues where
ASCs are derived from. Protocols are often established fol-
lowing the knowledge of developmental biology with
manipulation of key growth factors or signaling pathways
involved in germ layer and subsequent lineage speciﬁcation.
The ﬁrst organoid generated from mouse and human PSCs
are cortical tissues that displayed nicely the patterned
structures mimicking the early aspect of cortical develop-
ment (Eiraku et al., 2008; Gaspard et al., 2008). These
studies have demonstrated the intrinsic ability of corticoge-
nesis of stem cells when cultured in three-dimensional sys-
tem with appropriate exogenous signals. From there, a
variety of organoids of different tissues have been gener-
ated. The culture system in general is similar with the one
used for organogenesis from ASCs, in which the proper 3D
scaffold and biochemical factors are provided to induce the
differentiation of PSCs down speciﬁc lineages, and differ-
entiated cells will self-organize to form tissue-speciﬁc orga-
noids. Current organoids that have been reported to be
generated from mouse or human PSCs include stomach
(mouse/human) (McCracken et al., 2014; Noguchi et al.,
2015), intestine (mouse/human) (McCracken et al., 2011;
Ootani et al., 2009; Spence et al., 2011; Watson et al., 2014;
Workman et al., 2016), liver (human) (Ogawa et al., 2015;
Sampaziotis et al., 2015; Takebe et al., 2013; Takebe et al.,
2014), lung (human) (Dye et al., 2015), retina (mouse) (Ei-
raku et al., 2011), inner ear (mouse) (Koehler et al., 2013;
Koehler and Hashino, 2014), brain (mouse/human) (Eiraku
et al., 2008; Gaspard et al., 2008; Lancaster et al., 2013;
Lancaster and Knoblich, 2014; Mariani et al., 2012; Mugu-
ruma et al., 2010, 2015; Qian et al., 2016), pituitary gland
(mouse/human) (Ozone et al., 2016; Suga et al., 2011) and
kidney (human) (Takasato et al., 2015) (Table 2).
Construction of vascular and nervous systems
While a wide variety of organoids have been generated,
there are still huge gaps between in vitro generated
REVIEW Yingmin Sun and Qiurong Ding
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organoids and in vivo tissues. For example, organs in vivo
often consist of hierarchically branched vascular networks.
Almost all cells within an organ are surrounded by a few
hundred microns of a capillary to permit sufﬁcient nutrient
and oxygen supply. Also organs in vivo have integrated
peripheral nervous system that connects with the central
nervous system. The nervous system in general serves as a
communication relay, monitoring and coordinating internal
organ function and responds to changes in the external
environment. Thus, the construction of integrated vascular
network and peripheral nervous system in organoids are
important considerations in developing functional in vitro
tissues.
There have been several approaches established for
functional vascularization of generated organoids. One
approach is to seed endothelial cells within the culture sys-
tem that allows formation of blood vessels (Takebe et al.,
2013; Takebe et al., 2014). An example comes from the
generation of vascularized liver bud, in which hepatic
endoderm cells derived from hPSCs were co-cultured with
human umbilical vein endothelial cells (HUVECs) and
human mesenchymal stem cells (MSCs) to form “liver bud”.
Upon transplantation into mice, these liver buds connected
with the host vasculature and formed functional vascular
networks similar in density and morphology to those of
human adult livers. The other approach involves synthetic
scaffolds, which are used to create micro-engineered 3D
structures. Bio-printing methods can then be used for
seeding the channels with multiple types of vascular cells
(Visconti et al., 2010; Yin et al., 2016). For reconstruction of
integrated nervous system in organoids, the ﬁrst successful
work was recently published that presented engineered
hPSC-derived intestinal tissues with a functional enteric
nervous system (Workman et al., 2016). The strategy taken
was similar with seeding endothelial cells for vascularization.
hPSC-derived neural crest cells (NCCs) and human intesti-
nal organoids were mixed together through low-speed cen-
trifugation in 3D growth conditions. Upon transplantation
in vivo, these organoids formed neuroglial structures similar
to a myenteric and submucosal plexus, and moreover, dis-
played functional interstitial cells of Cajal as well as elec-
tromechanical coupling that regulated waves of propagating
contraction.
Other than lack of complete vascular and nervous sys-
tems, there are still key components lacking in current orga-
noids. For instance, stromal components including immune
cells that have important disease implications are missing,
which has largely limited the applications in modeling
inﬂammatory responses (e.g. to infection or drugs). Additional
challenges exist that the underlying mechanisms that how
stem cells self-organize remains obscure. It is therefore often
difﬁcult to control the cell type, cell organization, cell-cell and
cell-matrix interactions. Recent advances in biomaterials,
micro/nanotechnology and bioengineering approaches offer
some promising solutions (Yin et al., 2016). Biomimetic sys-
tems can be engineered to incorporate extrinsic biochemical
and biophysical signals to modulate the stem cell niche, to
control cell-cell and cell-matrix interaction, oxygen distribu-
tion, local pH levels and nutrient transport within organoids
(Yin et al., 2016).
GENOME ENGINEERING
While organoids can be generated from stem cells isolated
directly from patient’s tissues or from patient iPSCs for dis-
ease modeling, appropriate control is required to establish
disease-relevant phenotypes for mechanism study and
compound screenings. Availability of strict control groups is
becoming even more important in organoid systems, in
which huge systematic variations exist due to complicated
processes including derivation and differentiation of stem
cells as well as diverse engineering tools used for organoid
formation. The most rigorous possible control would be a cell
line that differ only with respect to disease mutations com-
pared to the original cell line, i.e., otherwise isogenic cell
lines. Such a strategy would require the ability to efﬁciently
introduce speciﬁc genetic alterations into the genomes of
hPSCs at will.
Fortunately, the discovery of different targeted nucleases
in recent years, especially the clustered regularly inter-
spaced short palindromic repeats (CRISPR)/CRISPR-asso-
ciated (Cas) system, has enabled researchers to accurately
manipulate genomic sequences in different cells and model
organisms. Within a couple of years, genome-editing tech-
nology has been rapidly developed for a variety of research
and translational applications, making it an extremely pow-
erful tool that can facilitate disease modeling by recapitu-
lating the genetic defects.
Although with different working modules, most of the
genome-editing tools share the same editing methodology
by introducing double stranded-breaks (DSBs) into a desired
genomic site. Cells react to DSBs by initiating DNA repair
processes, either through non-homology end joining (NHEJ)
or homology directed recombination (HDR). DNA repaired
by NHEJ is error-prone, which can introduce small insertions
or deletions (indels) into a genomic locus—causing frame-
shift thus knocking out the gene in coding region, or
destroying a DNA regulation element in non-coding region;
whereas DNA repaired by HDR can be used to introduce
precise single nucleotide alterations or insert a whole gene
into a speciﬁc genomic locus by providing an exogenous
DNA template. When multiple DSBs have been made
simultaneously into the cells (so called “multiplex”), chro-
matin structure changes, such as truncation, or even
translocation or duplication, can also be made, albeit at a
relatively lower rate (Hsu et al., 2014; Wang and Qi, 2016).
With genome editing tools, stem cell lines from patients
can be efﬁciently “cured” to correct the disease relevant
genetic variants to establish isogenic control groups
(Fig. 1A). In the case when patients carrying certain genetic
mutations are not accessible, wild-type stem cells can also
be introduced with genetic variants to create “patient” cell
Disease study with tissue organoids REVIEW









lines (Fig. 1A). Indeed, with this strategy a variety of genetic
variants, either in the same gene or in multiple genes, can be
introduced into a single cell line so that they are on the same
genetic and epigenetic background (Ding et al., 2013). This
allows for direct comparison of the effects of the different
genetic variants, setting up a panel of disease models for
study of mutation-speciﬁc disease phenotypes and for
screening of tailored disease treatments (Musunuru, 2013).
Not only genome editing tools can be used for engi-
neering DNA sequences, taking advantage of their ability to
target a speciﬁc genomic region, catalytically dead nucle-
ases, such as deactivated Cas9 (dCas9), can be fused to
functional effectors and carry out functions other than gen-
ome editing (Wang and Qi, 2016) (Fig. 1B). For example,
dCas9 has being fused with transcriptional activators or
repressors to regulate gene expression at the transcriptional
levels (Cheng et al., 2013; Gilbert et al., 2013; Perez-Pinera
et al., 2013a; Pinera et al., 2013b; Qi et al., 2013); with
epigenetic regulators (e.g. acetyltransferase and histone
demethylase) to manipulate the epi-status of a genomic
region (Amabile et al., 2016; Hilton et al., 2015; Kearns et al.,
2015; Thakore et al., 2015); with ﬂuorescent proteins (e.g.
green ﬂuorescent protein, GFP) for imaging of speciﬁc DNA
sequences (Chen et al., 2013; Ma et al., 2016a, b; Nelles
et al., 2016; Schmidt et al., 2016); and more recently with
cytidine deaminase enzymes to introduce the C->T (or
G->A) transitions, offering a more efﬁcient approach for base
editing than HDR (Komor et al., 2016; Ma et al., 2016a, b;
Nishida et al., 2016).
Besides making speciﬁc genetic or epigenetic alterations
to cells or model organisms, genome-editing tools, espe-
cially CRISPR/Cas9, have also been developed for high-
throughput genetic screenings (Fig. 1C). A variety of gRNA
libraries are currently available through Addgene (www.
addgene.org) that allows to screen tens of thousands of
genes genome-wide or a specialized group of genes (e.g.
kinases, transcription factors) for gene targets that are
responsible for a biological phenotype of interest. For
instance, screens have been performed to dissect genes or
signaling pathways involved in the development of tumor
drug resistance (Koike-Yusa et al., 2014; Konermann et al.,
2015; Gilbert et al., 2014; Shalem et al., 2014; Wang et al.,
2014; Zhou et al., 2014), transformation and metastasis of
cancer cells (Chen et al., 2015), pyroptotic cell death (Par-
nas et al., 2015; Shi et al., 2015) or mitochondrial deﬁciency
(Jain et al., 2016). Guide RNA libraries can also be cus-
tomized to target a speciﬁc non-coding genomic region in
order to dissect potential DNA regulating elements for a
certain cellular phenotype in a high-throughput manner




































Figure 1. Applications of genome engineering in disease modeling.Withgenomeediting tools, stemcell lines frompatients canbe
efﬁciently “cured” to correct the disease relevant genetic variants; or wild-type stem cells can also be introduced with genetic variants to
create “patient” cell lines for disease modeling (A). Catalytically dead nucleases, such as deactivated Cas9 (dCas9), can be fused to
different functional effectors andcarry outmolecular functionsother thangenomeediting (B). High-throughput genetic screenings canbe
developed using genome editing tools to illuminate genes or signaling pathways involved in disease development (C).
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paired-guided RNA CRISPR/Cas9 library has recently been
generated to screen for lincRNAs by performing multiplex
targeting to delete the entire lincRNA sequences (Zhu et al.,
2016). All these applications can greatly facilitate the
manipulation of genetic and epigenetic status in organoids
for disease modeling as well as obtaining the pathophysio-
logical insights for disease development and treatment.
DISEASE MODELING
Disease modeling with stem cells, especially with patient
derived iPSCs, has been applied to a variety of human dis-
eases (Musunuru, 2013). Although current stem cells-gen-
erated disease models mostly rely on 2D monocultures of a
single cell type, these cellular models have been proven to
be valuable in modeling human diseases with high physio-
logical relevance, and meantime offering abundant cellular
materials for high-throughput compound and genetic
screenings. One of the best examples came from studies of
human premature aging. One study focused on Hutchinson-
Gilford progeria syndrome (HGPS) disease, which is caused
by mutation in the LMNA gene. In this study, patient iPSC
and isogenic control iPSC lines were generated and differ-
entiated into vascular smooth muscle cells and ﬁbroblasts for
disease modeling (Liu et al., 2011). Furthermore, by setting
up a high-throughput siRNA screen with these cells, sup-
pressed NRF2 antioxidant activity has been successfully
identiﬁed as a driver mechanism in HGPS (Kubben et al.,
2016). Instead, a different study also focused on human
premature aging used a stem cell model generated by
knocking out exons of theWRN gene in wild-type embryonic
stem cell lines and subsequently differentiated to MSCs to
mimic the Werner syndrome (WS) (Zhang et al., 2015).
Studies with this cell model revealed a signiﬁcant role for
WRN in maintaining heterochromatin stability. A chemical
screen was later performed on these WRN-deﬁcient MSCs,
and interestingly, Vitamin C was found to be able to rescue
many of the aging features, suggesting it be a potential
treatment to alleviate Werner syndrome (Li et al., 2016).
With the recent development of organoid culture systems,
three-dimensional organoids offer new opportunities for
biomedical research in that diseases can be modeled at the
organ or tissue level. One of the most developed model
system with 3D organoids is from the intestine, representing
beautiful multiple approaches by which organoid disease
models can be generated and used to study diseases
(Fig. 2).
Infectious diseases
As mucin-rich barriers are established inside 3D organoids
from intestine, intestinal organoids that derived either from
crypt or PSCs offered a unique cellular system to study
pathophysiology of bacterial-epithelia interactions (Forbester
et al., 2015; Leslie et al., 2015; Wang et al., 2015; Wilson
et al., 2015; Zhang et al., 2014). Upon the invasiveness of
bacterial (e.g. strains of Salmonella and Clostridium), mor-
phologic changes and disruption of epithelial tight junctions
were observed in infected organoids, presenting one nice
experimental system to study host-bacterial interactions.
Similar studies have also been performed to study Heli-
cobacter pylori infection using gastric organoids, demon-
strating the potential for wider studies of the human
microbiome using 3D organoid models of epithelial tissues
(Bartfeld et al., 2015; Wroblewski et al., 2015).
Hereditary diseases
There have been several studies in which intestinal orga-
noids carrying speciﬁc disease-relevant mutations were
generated for pathophysiological study and for screening of
new pharmaceutical interventions. For example, a simple
and robust assay that allows the diagnosis, functional study
and identiﬁcation of personalized medicine was developed
using intestinal organoids derived from people who suffer
from cystic ﬁbrosis (Dekkers et al., 2013). In another study
focusing on multiple intestinal atresia (MIA)—a rare cause of
bowel obstruction, mutations in tetratricopeptide repeat
domain-7A (TTC7A) were identiﬁed from patients using
linkage analysis and whole-exome sequencing (Bigorgne
et al., 2014). Further studies using intestinal organoids
derived from MIA patients revealed an inversion of api-
cobasal polarity of the epithelial cells due to aberrantly
increased Rho kinase activity, suggesting a potential treat-
ment with pharmacological inhibition of Rho kinase. Another
recent study focused on Hirschsprung’s disease with an
impaired neural crest development being the underlying
cause (Workman et al., 2016). Study was carried out using
the most advanced intestinal organoids that have incorpo-
rated a functional enteric nervous system. With these orga-
noids, the molecular basis of pathophysiology of
Hirschsprung’s disease caused by a mutation in the
PHOX2B gene was carefully investigated.
Cancer
Organoids can also be adapted to develop in vitro models of
several types of malignancies from intestine/colon, stomach,
pancreas, prostate, brain and lung (Schweiger and Jensen,
2016). Cancer organoids can be directly generated from
patients’ primary cells, offering a model system that can
incorporate patient speciﬁc disease information. With such a
system, screens can be performed for treatments with high
efﬁcacy and minimal side effect (van de Wetering et al.,
2015). Organoids can also be used to study the role and
requirement of known driven mutations in cancer develop-
ment (Schweiger and Jensen, 2016). For instance, in one
study the most common mutations in colorectal cancer were
introduced to wild-type human intestinal organoids with
Disease study with tissue organoids REVIEW









different combinations (Drost et al., 2015). Results revealed
that organoids carrying mutants in all 4 genes (APC, TP53,
KRAS and SMAD4) can grow self-sufﬁciently and form solid
tumors with features of invasive carcinoma upon subcuta-
neous engrafting, whereas combined loss of APC and P53
was sufﬁcient to induce extensive aneuploidy. A similar study
compared the metastasis ability of intestinal organoids
carrying mutations in all 5 genes (APC, TP53, KRAS,
SMAD4 and PI3KCA) with another engineered organoids
derived from patient-derived chromosome-instable adeno-
mas (Matano et al., 2015). Results indicated that although
these ﬁve mutations are sufﬁcient for tumor development,
additional molecular lesions are required for invasive

















Drug discovery and toxicity test 
Screen for diagnostic and
 prognostic factors
Genotype-phenotype study
 of human genetics
Organs-on-a-chip
Study complex physiology
 e.g. human nutriology 
Drug discovery and toxicity test
Figure 2. Applications of organoid technology in basic and translational research. Tissue organoids can be derived from
patient iPSCs or ASCs. The in vitro development of organoids offers a cellular system for studying the contribution of various
signaling pathways in human tissue development and homeostasis. Established organoids can be used as a model system to study
infectious diseases or tissue speciﬁc responses to toxins. Organoids with patient-speciﬁc disease information can also be generated
for pathophysiology study, and can be expanded in a large scale for discovery of personalized treatment through high-throughput
screenings (A). Biobanks with organoids generated from human populations are being established, which will provide high valuable
resources that can be used to carry out preclinical efﬁcacy and toxicity test of candidate drugs, screen for diagnostic and prognostic
factors, and delineate genotype-phenotype causality in conjunction with current genetic studies (e.g. GWAS) (B). Complemented with
advances in bioengineering approaches, “organs-on-a-chip” can be built up containing multiple tissues that can offer an efﬁcient
system for drug discovery and study of more complex physiological processes, such as human nutriology (C).
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dissecting the causality of a speciﬁc mutation and/or com-
binations of mutations identiﬁed in individual patients as well
as in large cancer genomic studies.
Neurological diseases
Besides disease models generated with intestine organoids,
organoids derived from other tissues have also being used for
modeling diseases, such as liver, stomach and pancreas etc.
(Drost et al., 2015). In particular, brain organoids can be
generated that can be used to model various neurodevelop-
mental or neurodegenerative disorders that have beendifﬁcult
or impossible to model in animals. For example, brain orga-
noids derived from patient iPSCs have been used to study the
developmental pathogenesis of microcephaly caused by a
mutation in CDK5RAP2 (Lancaster et al., 2013). With further
development, it will not be surprising that cerebral organoids
can also be applied to model and study disorders such as
autism (Mariani et al., 2015), virus exposure (Qian et al., 2016)
and even adult-onset disorders like neurodegenerative dis-
eases in the future. It is worth mentioning that unlike cultured
primary neurons, PSCs can be maintained for a large number
of passages, thus these diseased brain organoids can be
expanded for high-throughput screenings for compounds for
disease treatment, offering a model system with huge poten-
tial in drug discovery to brain diseases.
It is clear that the generation of various 3D organoids
provides unprecedently a sophisticated model system that
has the potential to model a wide variety of human diseases;
still limitations exist at least with current systems. Compared
with monolayer model systems, which can be readily stan-
dardized, 3D organoids generation combines differentiation
of stem cells, aggregation of multi-types of cells and diverse
bioengineering approaches, making it extremely difﬁcult for
standardization and hard for groups to compare results
between systems. Another challenge comes from the mat-
uration of organoids in vitro. Although 3D organoids dis-
played in general more matured cellular phenotypes
compared to monolayer-cultured cells, most of organoids
cannot approach fully maturation until transplanted in vivo.
Furthermore, microenvironment and hormone levels, the
local pH levels, the nutrition status as well as the microbiome
of the human body cannot be fully reproduced in an in vitro
organoid. Thus it is critically important to have thorough
characterization of the in vitro organoid system with regard to
the extent of recapitulation of in vivo development before it is
used for biomedical research and therapeutics. Besides,
incorporation of functional vascular and nervous systems, as
well as stromal components for inﬂammatory studies in
organoids still await more development.
OUTLOOK
The common failures to translate promising preclinical drug
candidates into clinical success and the endeavors to realize
precision medicine highlight the urgent call for a model
system with easy accessibility, high physiological relevance
and ability to incorporate patient-speciﬁc disease back-
ground. Organoids derived from stem cells have proven to
be such a system that has the potential to recapitulate cru-
cial aspects of development, homeostasis and disease of
human body and to inherit patient-speciﬁc disease informa-
tion as well as has the capacity to expand indeﬁnitely.
With these advantages, organoids technology provides a
unique model system for a wide range of applications in both
basic research and translational studies. The in vitro devel-
opment of organoids itself offers a cellular system for
studying the contribution of various signaling pathways in
human tissue development and homeostasis. Established
organoids can also be used to study host-microbe interaction
and even responds to environmental and food processing-
generated toxins. When incorporated with disease related
information by biochemical and genetic manipulations,
human disease models can be established and used for
identiﬁcation of driver mutations and key pathophysiology
pathways in disease conditions. Furthermore, organoids
carrying speciﬁc disease information of a patient can be
grown in large scale for preclinical drug screenings for
treatment with high efﬁcacy and minimal side-effect that
being tailored to the patient’s requirement (Fig. 2A). Impor-
tantly, biobanks are being established collecting human
organoids that can potentially offer organoids of human
populations, which can be used for preclinical efﬁcacy and
toxicity tests of candidate drugs, screen for diagnostic and
prognostic factors, and study of genotype-phenotype
causality in conjunction with various genetic studies (e.g.
genome-wide association studies) (Fig. 2B). Moreover, it is
also clear that organoid technologies offer a potential large
source of donor tissues for transplantation use.
Complemented with advances in bioengineering approa-
ches, it is possible to build up organoids from different tis-
sues together or even a functional gastrointestinal system
using microﬂudic devices termed “organs-on-a-chip”
(Fig. 2C). Although still early in their development, several
organ-on-a-chip assay formats have already been evalu-
ated. For example, a four-organ-chip system was estab-
lished that included human liver, skin, intestine and kidney
(Maschmeyer et al., 2015). It is foreseen that generation of
such complex, stem-cell-based, multi-organ in vitro system
would allow us to model much more complicated physio-
logical processes, such as human nutriology (Ben-Zvi and
Melton, 2015).
Genome editing technology emerges as an extremely
powerful tool that can greatly advance organoid-based
research and therapies. With various genome editing tools,
genetic variants, epigenetic alterations, or even changes in
chromatin structure can be efﬁciently corrected from patient
cells or introduced into wild-type cells. A variety of human
disease models can therefore be established for patho-
physiology study and treatment development. Besides, dif-
ferent high-throughput genome editing platforms are offering
remarkable resources that can be adapted to screen for
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potential therapeutic targets in combination with disease
models. It is also possible that organoids can be edited to
possess extra functions that facilitate the in vitro organoid
formation and maturation. For instance, certain support cells
can be edited to enhance niche function or to cooperate
better with biomimetic scaffolds. Perhaps the most exciting
application lies in organoid-based therapeutics in the future.
Organoids derived from patients with hereditary diseases
can be “cured” with genome editing to correct the disease-
causing mutation(s), and functional organoids can then be
transplanted back into patients to improve tissue function-
ality. Altogether, although challenges exist that the current
organoids system still need substantial development, this
system have already found utility in many basic biological
and therapeutic ﬁelds to advance new knowledge and to
advance us closer to therapeutics for diseases that previ-
ously appeared untouchable.
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